Myeloproliferative Neoplasms | Specialty

Common Signs and Symptoms of Polycythemia Vera

January 30th 2020

An Overview of Myeloproliferative Neoplasms

January 30th 2020

Dr. Kremyanskaya on Effect of CPI-0610 in Patients With Myelofibrosis

January 29th 2020

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

Dr. Mesa on JAK Inhibitors in the Pipeline for Myelofibrosis

January 28th 2020

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Dr. Gerds on Addressing Anemia in Myelofibrosis

January 28th 2020

Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.

Dr. Dunavin on Ongoing Research for Myelofibrosis Treatments

January 28th 2020

Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.

Genomic Sequencing and Identifying Driver Mutations in AML and MDS

January 25th 2020

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

January 24th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Dr. Nagalla on the Utility of DOACs in MPN-Associated Thrombosis

January 22nd 2020

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in patients with a myeloproliferative neoplasm–associated venous thromboembolism.

Dr. Dunavin on Frontline Treatment in Myelofibrosis

January 21st 2020

Neil Dunavin, MD, MS, discusses frontline treatment in myelofibrosis.

Emerging Agents, Treatment Selection Criteria Key to Improving Outcomes in Myelofibrosis

January 20th 2020

Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.

Dr. Garcia on Research With the Combination of Navitoclax/Ruxolitinib in Myelofibrosis

January 18th 2020

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

January 17th 2020

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Dr. Mesa on the Efficacy of Fedratinib in Patients With Myelofibrosis and Low Platelet Counts

January 16th 2020

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

January 15th 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

NEJM Data Show Luspatercept Alleviates Anemia in Patients With MDS

January 15th 2020

Treatment with luspatercept-aamt reduced the severity of anemia in patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts who require red blood cell transfusions.

Dr. Gerds on Future Treatment of Patients With Myeloproliferative Neoplasms

January 14th 2020

Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.

Dr. Dunavin on Treatment Considerations in Myelofibrosis

January 10th 2020

Neil Dunavin, MD, MS, assistant professor of medicine, School of Medicine, University of California, San Francisco (UCSF), UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment considerations in myelofibrosis.

Dr. Rampal on Treatment Options in Polycythemia Vera

January 8th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

CPI-0610 Shows Strong Efficacy Signals for Advanced Myelofibrosis

December 10th 2019

CPI-0610 showed promising spleen volume responses and a meaningful reduction in total symptom score as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis.